2 weeks ago
Lord’s Mark Plans Healthcare Expansion, Revenue Growth and Energy Demerger
Lord’s Mark is a company that works in healthcare, diagnostics, technology and renewable energy.
It expects to earn at least ₹1,550 crore in revenue during FY2027.
It also expects to make at least ₹178 crore in profit after tax.
The company wants to separate its renewable energy and LED business into another company.
It plans to bring CAR-T cancer treatment to India through five centres.
It also plans to open oncology hospitals in smaller cities and 50 dialysis centres across India.
The company says these projects could help more patients receive medical care.
It is also setting up businesses in the UK and Switzerland to sell Indian-made diagnostic products.
The company says its genomic testing and medical software products have reached important development milestones.
Lord’s Mark Industries projects FY2027 revenue of at least ₹1,550 crore and PAT of at least ₹178 crore.
The company proposes separating its Renewable Energy and LED business into Lords Shakti Power Limited by March 2027.
Lord’s Mark plans to introduce CAR-T therapy across five Indian centres and build oncology hospitals in tier-2 cities.
The company aims to establish 50 dialysis centres using its proprietary RENALOS machines by March 2027.
Its international expansion includes subsidiaries in the UK and Switzerland, while OneDNA trials and Biomescan licensing have advanced.
- Who
- Lord’s Mark Industries Limited, its Managing Director Sachidanand Upadhyay, and its subsidiaries.
- What
- The company announced healthcare, oncology, diagnostics and international expansion plans, FY2027 financial projections, and a proposed renewable-energy business demerger.
- Where
- India, including Mumbai, Bangalore, Vapi and Solapur, as well as planned operations in the UK and Switzerland.
- When
- The plans primarily target FY2027 and March 2027; a planned ₹200 crore debt raise is scheduled for December 2026.
- Why
- To expand healthcare access, develop recurring service revenues, improve capital allocation, and create international markets for its diagnostic products.
Key facts
- FY2027 revenue projection
- At least ₹1,550 crore, representing more than 20% growth compared with FY2026.
- FY2027 PAT projection
- At least ₹178 crore, with a projected 11.4% margin.
- Proposed energy demerger
- The Renewable Energy and LED business would be separated into Lords Shakti Power Limited by March 2027.
- CAR-T rollout
- An exclusive agreement is planned to bring CAR-T cell therapy to India across five centres, beginning with Mumbai and Bangalore.
- Oncology hospitals
- Two planned 70-bed pilot hospitals in Vapi and Solapur would be supported by a proposed ₹200 crore debt raise.
- Dialysis expansion
- The company plans to establish 50 company-operated dialysis centres across India by March 2027.
- International subsidiaries
- Lords Mark Industries UK Limited has been incorporated, and Lords Mark Industries Swiss Limited is being established.
Quotes
Sachidanand Upadhyay, Managing Director, Lord's Mark Industries Ltd.
Managing Director of Lord's Mark Industries
“"The guidance we have issued reflects the strength of our existing operations, with top‑line growth of at least 20% and PAT growth of at least 50%. The subsequent announcements are what we build on top of them: cancer care reaching India's rural districts, advanced CAR‑T therapy at affordable prices for Indian patients, and Indian‑made diagnostics serving laboratories from the UK to Switzerland."”
livemint.com
“"Lord's Mark today stands at the most important inflection point in its history. Over the past decade we have built profitable, scaled businesses in diagnostics and renewable energy, the foundations of which now fund our next chapter."”
livemint.com





